Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
UNKNOWNN/A

Mobile Application to Collect PRO Data in NET Patients

Sponsor: King's College Hospital NHS Trust

NCT ID: NCT04324502

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Not specified by the sponsor
How long the study runs
Study runs about 72 months (dates as stated)
About the drug or intervention
Not specified by the sponsor
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
18 Years and over
Who
All
Number of participants
2,000
Started
2020-07-20
Last checked
2020-03

Plain English Summary

What is this study?

  • • Testing a new treatment for neuroendocrine neoplasms (tumours)
  • • Clinical study - 2,000 participants
  • • Observational trial to assess the feasibility of monitoring patient reporting symptoms via mobile devices

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with neuroendocrine neoplasms (tumours)

Where?

  • • London - King's College Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Observational trial to assess the feasibility of monitoring patient reporting symptoms via mobile devices

More detail

Neuroendocrine tumours (NET) are uncommon cancers with varied presentation. Patients are treated in specialist centres, and may sometimes have up to 4 lines of treatment; with the attendant complications. To date there has been no study capturing precisely patient reported outcomes (PROMs) and changes in QoL post treatment. We have worked with the national patient charity and support group (Neuroendocrine Tumour Patient Foundation) and UKINETS, to develop a mobile application that will allow patients to capture details of their symptoms, as well as changes to quality of life during and post treatment. The application has been designed as an aide to patients, capturing details of their illness, treatment and interaction with the healthcare team (appointments). This study aims to assess whether use of mobile app technology is helpful for patients undergoing medical and surgical therapy for neuroendocrine tumours. The trial is non-invasive and allows participants to record daily symptoms and raise alerts whilst they are undergoing different therapies. Health related quality of life during therapy will be assessed at specified times using EORTC validated questionnaires. The study also aims to investigate any difference in clinicians' response to PROMs; and the time taken to institute change, in any. Participants are able to download the application from their mobile device app store from whichever location they wish, provided that they have regular internet access to download the app. Participants will be asked to provide daily responses pertaining to their health outcomes (PROs) in addition to completing validated quality of life questionnaires (EORTC CLQ - C30 and EORTC GINET21) at regular intervals over a 4 year period, prior to their treatment starting and throughout their treatment (months 0,3,6,12; and 6 monthly thereafter). This data will be stored in a research-specific database of de-identified patient-reported outcomes on quality of life and health.There are added features for participants to enter their medication information and appointments in the outpatient clinic; functionality to set reminders to take their medication; as well as reminders for upcoming hospital visits; and links to email addresses to contact their primary care teams. Clinicians are able to access the data to identify problems and track response to interventions. The data will be stored in an encrypted format on the secure servers of Ampersand Health Ltd, who will export the data to the Chief Investigator at King's College Hospital at the end of the study.

Neuroendocrine Neoplasms (Tumours)

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

What the study is looking for

  • ✓confirmed by a biopsy diagnosis of a NET
  • ✓Planned treatment for NET
  • ✓Able to give agreement to take part
  • ✓Able to understand the language of the questionnaires
  • ✓A minimum expected survival of 6 months

Who cannot take part

  • ✗Concurrent malignancies for which they are undergoing treatment
  • ✗No smartphone / device
  • ✗Any physical, psychological or comprehension problems that prevents completion of questionnaires.
See the full criteria
Inclusion Criteria: * Histologically confirmed diagnosis of a NET * Planned treatment for NET * Able to give informed consent * Able to understand the language of the questionnaires * A minimum expected survival of 6 months * All performance status is acceptable * 18 years of age or over Exclusion Criteria: * Concurrent malignancies for which they are undergoing treatment * No smartphone / device * Any physical, psychological or comprehension problems that prevents completion of questionnaires.

Where Is This Study? (1 UK site)

King's College Hospital

London SE5 9RS, United Kingdom

Recruiting
Site contact (verified)

How to Get in Touch

Raj Srirajaskanthan

Sponsor contact

CONTACT

0203 299 3255 r.srirajaskanthan@nhs.net
Data sourced from ClinicalTrials.gov · Last verified: 2020-03